Emerging drugs for sarcopenia: age-related muscle wasting

Bibliography

• ROUBENOFF R: Sarcopenia: effects on body composition and function. Cerontol.(2003) 58A:1012–1017.
   Google Scholar
• HUNTER GR, McCARTHY JP,BAMMAN MM: Effects of resistance training on older adults. Sports Med. (2004) 34:329–348.
   PubMed Web of Science ®Google Scholar
• LARSSON L, ANSVED T: Effects of ageing on the motor unit. Prog. Neurobiol (1995) 45:397–458.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review on the effects of ageing on neuromuscular function.
   Google Scholar
• LARSSON L, RAMAMURTHY B: Aging-related changes in skeletal muscle. Drugs Aging (2000) 17:303–316.
   PubMed Web of Science ®Google Scholar
• MASORO EJ: Aging. In: Handbook of Physiology, Section 11. MASORO EJ (Ed.), Oxford University Press, New York (1995):681.
   Google Scholar
• •Definitive volume describing a broad range of topics relevant to the physiology of ageing.
   Google Scholar
• MORLEY JE, BAUMGARTNER RN, ROUBENOFF R, MAYER J, NAIR KS: Sarcopenia. I Lab. Clin. Med. (2001) 137:231–243.
   PubMed Web of Science ®Google Scholar
• NAVARRO A, LOPEZ-CEPERO J, SANCHEZ DEL PINO MJ: Skeletal muscle aging. Front. Biosci. (2001) 6:D26–D44.
   PubMed Web of Science ®Google Scholar
• FAULKNER JA, BROOKS SV, ZERBA E:Muscle atrophy and weakness with aging: contraction-induced injury as an underlying mechanism. Cerontol. (1995) 50A:124–129.
   Google Scholar
• TSENG BS, MARSH DR, HAMILTON MT, BOOTH FW: Strength and aerobic training attenuate muscle wasting and improve resistance to the development of disability with aging.Cerontol. (1995) 50A:113–119.
   Google Scholar
• ROOS MR, RICE CL, VANDERVOORT AA: Age-related changes in motor unit function. (1997) Muscle Nerve 20:679–690.
   PubMed Web of Science ®Google Scholar
• DOHERTY TJ: Invited review: aging andsarcopenia. Appl. Physiol (2003) 95:1717–1727.
   PubMed Web of Science ®Google Scholar
• GREENLUND LJ, NAIR KS: Sarcopenia-consequences, mechanisms, and potential therapies. Mech. Ageing Dev. (2003) 124:287–299.
   PubMed Web of Science ®Google Scholar
• CARMELI E, COLEMAN R, REZNICK AZ: The biochemistry of aging muscle. Exp. Cerontol. (2002) 37:477–489.
   PubMed Web of Science ®Google Scholar
• VANDERVOORT AA: Aging of the human neuromuscular system. Muscle Nerve(2002) 25:17–25.
   PubMed Web of Science ®Google Scholar
• WILSON MM, MORLEY JE: Invited review: aging and energy balance. .I. Appl Physiol (2003) 95:1728–1736.
   PubMed Web of Science ®Google Scholar
• KAMEL HK: Sarcopenia and aging. Num. Rev (2003) 61:157–167.
   Web of Science ®Google Scholar
• BARTON E, MORRIS C: Mechanisms and strategies to counter muscle atrophy.Cerontol. (2003) 58:M923–M926.
   PubMedGoogle Scholar
• VOLPI E, NAZEMI R, FUJITA S: Muscletissue changes with aging. Curt: Opin. Clin. Num. Metab. Care (2004) 7:405–410.
   PubMed Web of Science ®Google Scholar
• LUFF AR: Age-associated changes in the innervation of muscle fibers and changes in the mechanical properties of motor units.Annals New York Acad. Sci. (1998) 854:92–101.
   PubMed Web of Science ®Google Scholar
• BOOTH FW, WEEDEN SH, TSENG BS: Effect of aging on human skeletal muscle and motor function. Med. Sci. Sports Exerc.(1994) 26:556–560.
   PubMed Web of Science ®Google Scholar
• LEXELL J: Strength training and muscle hypertrophy in older men and women. Top. Ceriam. Rehabil. (2000) 15:41–46.
   Web of Science ®Google Scholar
• LEXELL J: Evidence for nervous system degeneration with advancing age. Num(1997) 127:1011S–1013S.
   Google Scholar
• CHAN KM, DOHERTY TJ, BROWN WF: Contractile properties of human motor units in health, aging, and disease. Muscle Nerve (2001) 24:1113–1133.
   PubMed Web of Science ®Google Scholar
• SCHULTZ AB, ASHTON-MILLER JA,ALEXANDER NB: What leads to age and gender differences in balance maintenance and recovery. Muscle Nerve (2001)\(Suppl. 5):S60–S64.
   Google Scholar
• HEDSTROM M: Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels. Acta Physic] Scand. (1999) 167:347–350.
   PubMedGoogle Scholar
• LARSSON L, EDSTROM L: Effects of ageon enzyme-histochemical fibre spectra and contractile properties of fast- and slow-twitch skeletal muscles in the rat. J. Neurol Sci. (1986) 76:69–89.
   PubMed Web of Science ®Google Scholar
• NARAYANAN N, JONES DL, XU A, YU JC: Effects of aging on sarcoplasmic reticulum function and contraction duration in skeletal muscles of the rat. Am. J. Physiol (1996) 271:C1032–C1040.
   PubMed Web of Science ®Google Scholar
• FRONTERA WR, SUH D, KRIVICKAS LS, HUGHES VA, GOLDSTEIN R, ROUBENOFF R: Skeletal muscle fiber quality in older men and women. Am. I Physiol (2000) 279:C611–C618.
   PubMed Web of Science ®Google Scholar
• FRONTERA WR, HUGHES VA, FIELDING RA, FIATARONE MA, EVANS WJ, ROUBENOFF R: Aging of skeletal muscle: a 12-yr longitudinal study.Appl. Physiol (2000) 88:1321–1326.
   PubMed Web of Science ®Google Scholar
• PLANT DR, LYNCH GS: Excitation-contraction coupling and sarcoplasmic reticulum function in mechanically skinned fibres from fast skeletal muscles of aged mice. J. Physiol (2002) 543:169–176.
   PubMed Web of Science ®Google Scholar
• MARGRETH A, DAMIANI E,BORTOLOSO E: Sarcoplasmic reticulum in aged skeletal muscle. Acta Physic] Scand. (1999) 167:331–338.
   PubMedGoogle Scholar
• DELBONO O, O'ROURKE KS, ETTINGER WH: Excitation-calcium release uncoupling in aged single human skeletal muscle fibers. J. Memb. Biol. (1995) 148:211–222.
   PubMed Web of Science ®Google Scholar
• DAMIANI E, LARSSON L,MARGRETH A: Age-related abnormalities in regulation of the ryanodine receptor in rat fast-twitch muscle. Cell Calcium (1996) 19:15–27.
   PubMed Web of Science ®Google Scholar
• FERRINGTON DA, KRAINEV AG, BIGELOW DJ: Altered turnover of calcium regulatory proteins of the sarcoplasmic reticulum in aged skeletal muscle. J. Biol. Chem. (1998) 273:5885–5891.
   PubMed Web of Science ®Google Scholar
• WELLE S, THORNTON C, STATT M: Myofibrillar protein synthesis in young and old human subjects after three months of resistance training. Am. J. Physic] (1995) 31:E422–E427.
   Google Scholar
• YARASHESKI KE, PAK-LODUCA J, HASTEN DL, OBERT KA, BROWN M, SINACORE DR: Resistance exercise training increases mixed muscle protein synthesis rate in frail women and men 76 yr old. Am. J. Physiol (1999) 277:E118–E125.
   PubMed Web of Science ®Google Scholar
• HASTEN DL, PAK-LODUCA J, OBERT KA, YARASHESKI KE: Resistance exercise acutely increases MHC and mixed muscle protein synthesis rates in 78-84 and 23-32 yr olds. Am. Physiol (2000) 278:E620–E626.
   PubMed Web of Science ®Google Scholar
• VOLPI E, SHEFFIELD-MOORE M, RASMUSSEN BB, WOLFE RR: Basal muscle amino acid kinetics and protein synthesis in healthy young and older men. JAMA (2001) 286:1206–1212.
   PubMed Web of Science ®Google Scholar
• KIMBALL SR, O'MALLEY JP, ANTHONY JC, CROZIER SJ, JEFFERSON LS: An assessment of biomarkers of protein anabolism in skeletal muscle during the lifespan of the rat: sarcopenia despite elevated protein synthesis. Am. I Physiol Endocrinol Metab. (2004) 287:E772–E780.
   PubMed Web of Science ®Google Scholar
• BALAGOPAL P, PROCTOR D, NAIR KS: Sarcopenia and hormonal changes. Endocrine (1997) 7:57–60.
   PubMed Web of Science ®Google Scholar
• PROCTOR DN, BALAGOPAL P, NAIR KS. Age-related sarcopenia in humans is associated with reduced synthetic rates of specific muscle proteins. J. Nuti: (1998) 128:351S–355S.
   Google Scholar
• LYNCH GS: Novel therapies for sarcopenia: ameliorating age-related changes in skeletal muscle. Expert Opin. Ther: Patents (2002) 12: 11–27.
   Google Scholar
• LYNCH GS: Update on therapies for sarcopenia: novel approaches for age-related muscle wasting and weakness. Expert Opin. Ther. Patents (2004) 14:1329–1344.
   Web of Science ®Google Scholar
• JUHN M: Popular sports supplements and ergogenic aids. Sports Med. (2003) 33:921–939.
   PubMed Web of Science ®Google Scholar
• BROEDER CE: Oral andro-related prohormone supplementation: do the potential risks outweigh the benefits? Can. J. Appl. Physiol (2003) 28:102–116.
   PubMedGoogle Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal resultsfrom the Women's Health Initiative randomized controlled trial. JAMA (2002) 288:321–333.
   PubMed Web of Science ®Google Scholar
• SHUMAKER SA, LEGAULT C, RAPP SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 289:2651–2662.
   PubMed Web of Science ®Google Scholar
• LYNCH GS: Tackling Australia's future health problems: developing strategies to combat sarcopenia - age-related muscle wasting and weakness. Intern. Med. J. (2004) 34:294–296.
   PubMed Web of Science ®Google Scholar
• NEGRO-VILAR A: Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. I Clin. Endocrinol Metab. (1999) 84:3459–3462.
   Google Scholar
• MARHEFKA CA, GAO W, CHUNG K et al.: Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators.Med. Chem. (2004) 47:993–998.
   Web of Science ®Google Scholar
• GAO W, KEARBEY JD, NAIR VA et al: Comparison of the pharmacological effects of a novel selective androgen receptor modulator (SARM), the 5{alpha}-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia (BPH). Endocrinology (2004) (In press).
   Google Scholar
• FLEG JL, SCHULMAN S, O'CONNOR F et al.: Effects of acute beta-adrenergic receptor blockade on age-associated changes in cardiovascular performance during dynamic exercise. Circulation (1994) 90:2333–2241.
   PubMed Web of Science ®Google Scholar
• PEEL C, MOSSBERG KA: Effects of cardiovascular medications on exercise responses. Phys. Ther. (1995) 75:387–396.
   PubMed Web of Science ®Google Scholar
• SLEIGHT P: Current options in the management of coronary artery disease. Am. Cardiol (2003) 92:4N–8N.
   Google Scholar
• SINGH MA: Exercise comes of age: rationale and recommendations for a geriatric exercise prescription. I Cerontol (2002) 57:M262–M282.
   PubMed Web of Science ®Google Scholar
• ••Excellent review that emphasises the role ofexercise for promoting functional independence in the elderly.
   Google Scholar
• JANSSEN I, SHEPARD DS, KATZMARZYK PT, ROUBENOFF R: The healthcare costs of sarcopenia in the United States. I Am. Ceriatr. Soc. (2004) 52:80–85.
   PubMed Web of Science ®Google Scholar
• DELBONO 0: Neural control of aging skeletal muscle. Aging Cell (2003) 2:21–29.
   PubMed Web of Science ®Google Scholar
• RENNIE MJ, WACKERHAGE H, SPANGENBURG EE, BOOTH FW: Control of the size of the human muscle mass. Ann. Rev Physiol (2004) 66:799–828.
   PubMed Web of Science ®Google Scholar
• •Clear description of the signalling pathways regulating muscle growth.
   Google Scholar
• GUTTRIDGE DC: Signaling pathways weigh in on decisions to make or break skeletal muscle. Carr: Opin. Clin. Nuti: Metab. Care (2004) 7:443–450.
   PubMed Web of Science ®Google Scholar
• GLASS DJ: Molecular mechanisms modulating muscle mass. Trends Ma Med. (2003) 9:344–350.
   PubMed Web of Science ®Google Scholar
• GLASS DJ: Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nature Cell Biol. (2003) 5:87–90.
   PubMed Web of Science ®Google Scholar
• •Brief but excellent review describing the mechanisms responsible for muscle growth and atrophy.
   Google Scholar
• ROMMEL C, BODINE SC, CLARKE BA et al.: Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/ mTOR and PI(3)K/Akt/GSK3 pathways. Nature Cell Biol. (2001) 3:1009–1013.
   PubMed Web of Science ®Google Scholar
• BODINE SC, STITT TN,GONZALEZ M et al.: Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. (2001) 3:1014–1019.
   PubMed Web of Science ®Google Scholar
• STITT TN, DRUJAN D, CLARKE BA et al.: The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Ma Cell (2004) 14:395–403.
   PubMed Web of Science ®Google Scholar
• BASSEL-DUBY R, OLSON EN: Role of calcineurin in striated muscle: development, adaptation, and disease. Biochem. Biophys. Res. Commun. (2003) 311:1133–1141.
   PubMed Web of Science ®Google Scholar
• CHAKKALAKAL JV, HARRISON MA, CARBONETTO S, CHIN E, MICHEL RN, JASMIN BJ: Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum. Ma Genet. (2004) 13:379–388.
   PubMed Web of Science ®Google Scholar
• CHAKKALAKAL JV, STOCKSLEY MA,HARRISON MA et al.: Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc. Nati Acad. Sci. USA (2003) 100:7791–7796.
   PubMed Web of Science ®Google Scholar
• STUPKA N, GREGOREVIC P, PLANT DR, LYNCH GS: Inhibition of the calcineurin signalling pathway with cyclosporine A impairs muscle regeneration in young mdx mice. Acta Neuropathol (2004) 107:299–310.
   PubMed Web of Science ®Google Scholar
• HORNBERGER TA, STUPPARD R, CONLEY KE et al.: Mechanical stimuli regulate rapamycin-sensitive signaling by a phosphoinositide 3-kinase, protein kinase B and growth factor independent mechanism. Biochem. J. (2004) 380:795–804.
   PubMed Web of Science ®Google Scholar
• LYNCH GS: Novel therapies for musculardystrophy and other muscle wasting conditions. Expert Opin. Tiler. Patents 11:587–601.
   Web of Science ®Google Scholar
• BHASIN S: Testosterone supplementation for aging-associated sarcopenia. Gerontol (2003) 58:1002–1008.
   Web of Science ®Google Scholar
• HERBST KL, BHASIN S: Testosterone action on skeletal muscle. Carr: Opin. Clin. Nutr. Metab. Care (2004) 7:271–277.
   PubMed Web of Science ®Google Scholar
• TOO GOOD AA. Growth hormone (GH) status and body composition in normal ageing and in elderly adults with GH deficiency. Horm. Res. (2003)60\(Suppl. 1):105–111.
   Google Scholar
• ZDANOWICZ MM, TEICHBERG S: Effects of insulin-like growth factor-1/ binding protein-3 complex on muscle atrophy in rats. Exp. Biol. Med. (2003) 228:891–897.
   Web of Science ®Google Scholar
• HARMAN SM, BLACKMAN MR: The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm. Res. (2003)60\(Suppl. 1):121–124.
   PubMedGoogle Scholar
• MACHIDA S, SPANGENBURG EE, BOOTH FW: Forkhead transcription factor Fox01 transduces insulin-like growth factor's signal to p27Kipl in primary skeletal muscle satellite cells. .1 Cell Physiol (2003) 196:523–531.
   PubMed Web of Science ®Google Scholar
• HULL KL, HARVEY S: Growth hormone therapy and quality of life: possibilities, pitfalls and mechanisms. Endocrinol (2003) 179:311–333.
   Web of Science ®Google Scholar
• BARTKE A: Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice. Neuroendocrinology (2003) 78:210–216.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, ISHIDA K, ITOH K et al.: IGF-I gene transfer by electroporation promotes regeneration in a muscle injury model. Gene Tiler. (2003) 10:612–620.
   Web of Science ®Google Scholar
• MESSI ML, DELBONO 0: Target-derivedtrophic effect on skeletal muscle innervationin senescent mice. NeuroscL (2003) 23:1351–1359.
   PubMed Web of Science ®Google Scholar
• MUSARO A, GIACINTI C,BORSELLINO G et al: Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc. Nati Acad. Sci. USA (2004)101:1206–1210.
   PubMed Web of Science ®Google Scholar
• HADDAD F, ADAMS GR: Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles. I Appl. Physiol (2004) 96:203–210.
   PubMed Web of Science ®Google Scholar
• ROUBENOFF R, PARISE H,PAYETTE HA et al.: Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am.j Med. (2003) 115:429–435.
   PubMed Web of Science ®Google Scholar
• GROUNDS MD: Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology (2002) 3:19–24.
   PubMed Web of Science ®Google Scholar
• ADAMS GR: Insulin-like growth factor in muscle growth and its potential abuse by athletes. Br. Sportsmed. (2000) 34:412–413.
   PubMed Web of Science ®Google Scholar
• MUSARO A, ROSENTHAL N: The role of local insulin-like growth factor-1 isoforms in the pathophysiology of skeletal muscle. Current Genomics (2002) 3:149–162.
   Google Scholar
• WINN N, PAUL A, MUSARO A, ROSENTHAL N: Insulin-like growth factor isoforms in skeletal muscle aging, regeneration and disease. Cold Springs Harbour Symposium on Quantitative Biology LXVII (2002):507–518.
   PubMedGoogle Scholar
• OWINO V, YANG SY, GOLDSPINK G: Age-related loss of skeletal muscle function and the inability to express the autocrine form of insulin-like growth factor-1 (MGF) in response to mechanical overload. FEBS Lett. (2001) 505:259–263.
   PubMed Web of Science ®Google Scholar
• HAMEED M, ORRELL RW,COBBOLD M, GOLDSPINK G, HARRIDGE SD: Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise.Physiol (2003) 547:247–254.
   Web of Science ®Google Scholar
• SHAVLAKADZE T, DAVIES M,WHITE JD, GROUNDS MD: Early regeneration of whole skeletal muscle grafts is unaffected by overexpression of IGF-1 in MLC/mIGF-1 transgenic mice..1 Histochem. Cytochem. (2004) 52:873–883.
   Google Scholar
• GOLDSPINK G: Age-related muscle lossand progressive dysfunction inmechanosensitive growth factor signaling. Ann. NY Acad. ScL (2004) 1019:294–298.
   PubMed Web of Science ®Google Scholar
• YANG SY, GOLDSPINK G: Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. (2002) 522:156–160.
   PubMed Web of Science ®Google Scholar
• BARTON-DAVIS ER, SHOTURMA DI, MUSARO A, ROSENTHAL N, SWEENEY HL: Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc. Natl Acad. Sci. USA (1998) 95:15603–15607.
   PubMed Web of Science ®Google Scholar
• •Clear demonstration of the rationale for, and efficacy of IGF-I therapies for sarcopenia.
   Google Scholar
• BARTON ER, MORRIS L, MUSARO A, ROSENTHAL N, SWEENEY HL: Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdxmice.j Cell Biol. (2002) 157:137–148.
   PubMed Web of Science ®Google Scholar
• HAMEED M, HARRIDGE SD, GOLDSPINK G: Sarcopenia and hypertrophy: a role for insulin-like growth factor-1 in aged muscle? Exerc. Sport Sci. Rev (2002) 30:15–19.
   PubMed Web of Science ®Google Scholar
• HAMEED M, LANGE KH, ANDERSEN JL, SCHJERLING P, KJAER M, HARRIDGE SD, GOLDSPINK G: The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. .1 Physiol (2004) 555:231–240.
   PubMed Web of Science ®Google Scholar
• SHAVLAKADZE T, GROUNDS MD: Therapeutic interventions for age-related muscle wasting: importance of innervation and exercise for preventing sarcopenia. In: Modulating aging and longevity RATTAN S (Ed.) Kluwer Academic Publishers, The Netherlands (2003):139–166.
   Google Scholar
• LYNCH GS, SHAVLAKADZE T, GROUNDS MD: Strategies to reduce age-related skeletal muscle wasting. In: Aging Interventions and Therapies. RATTAN S (Ed.) Kluwer Academic Publishers, The Netherlands (2004) 63–84.
   Google Scholar
• NEFF NT, PREVETTE D,HOUENOU LJ et al.: Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. Neurobiol (1993) 24:1578–1588.
   Google Scholar
• LEWIS ME, NEFF NT, CONTRERAS PC et al.: Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp. Neurol (1993) 124:73–88.
   PubMed Web of Science ®Google Scholar
• CONTRERAS PC, STEFFLER C, VAUGHT JL: rhIGF-I enhances functional recovery from sciatic crush. Time-course and dose-response study. Ann. NYAcad. Sci. (1993) 692:314–316.
   PubMed Web of Science ®Google Scholar
• CONTRERAS PC, STEFFLER C, YU E, CALLISON K, STONG D, VAUGHT JL: Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice.' Pharmacol Exp. The]: (1995) 274:1443–1449.
   PubMed Web of Science ®Google Scholar
• VOS PE, KOPPESCHAAR HP,DE VRIES WR, WOKKE JH: Insulin-like growth factor-I: clinical studies. Drugs Today (1998) 34:79–90.
   PubMed Web of Science ®Google Scholar
• GINSBERG G, LOWE S: Costeffectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature. Pharmacoeconomics (2002) 20:367–387.
   PubMed Web of Science ®Google Scholar
• MORSE MA: Technology evaluation: VEGF165 gene therapy, Valentis, Inc. Curt: Opin. Mol The]: (2001) 3:97–101.
   PubMed Web of Science ®Google Scholar
• ROLLAND AP, MUMPER RJ: Plasmid delivery to muscle: recent advances in polymer delivery systems. Adv. Drug Deily. Rev (1998) 30:151–172.
   PubMed Web of Science ®Google Scholar
• RAGHAVACHARI N, FAHL WE: Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles. Pharm. Sci. (2002) 91:615–622.
   PubMed Web of Science ®Google Scholar
• SMITH LC, NORDSTROM JL: Advances in plasmid gene delivery and expression in skeletal muscle. Curt: Opin. Mol. The]: (2000) 2:150–154.
   PubMed Web of Science ®Google Scholar
• BLEZINGER P, YIN G, XIE L et al: Intravenous delivery of an endostatin gene complexed in cationic lipid inhibits systemic angiogenesis and tumor growth in murine models. Angiogenesis (1999) 3:205–210.
   PubMedGoogle Scholar
• QUEZADA A, LARSON J, FRENCH M et al.: Biodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models. Pharm. Pharmacol (2004) 56:177–185.
   PubMed Web of Science ®Google Scholar
• FEWELL JG, NORDSTROM JL: Regulated production of proteins from muscle using gene transfer: potential therapeutic applications. Expert Opin. Biol. The]: (2003) 3:277–291.
   PubMed Web of Science ®Google Scholar
• ALILA H, COLEMAN M, NITTA H et al.: Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum. Gene The]: (1997) 8:1785–1795.
   PubMed Web of Science ®Google Scholar
• KASPAR BK, LLADO J, SHERKAT N, ROTHSTEIN JD, GAGE FH: Retrograde viral delivery of I GF- 1 prolongs survival in a mouse ALS model. Science (2003) 301:839–842.
   PubMed Web of Science ®Google Scholar
• NORMAN P: SomatoKine. Insmed. Carr. Opin. Investig. Drugs (2003) 4:466–471.
   PubMedGoogle Scholar
• SVANBERG E, OHLSSON C, KIMBALL SR, LUNDHOLM K: rhIGF-I/IGFBP-3 complex, but not free rhIGF-I, supports muscle protein biosynthesis in rats during semistarvation. Eur. j Chit. Invest. (2000) 30:438–446.
   PubMed Web of Science ®Google Scholar
• SAVAGE MO, CAMACHO-HUBNER C, DUNGER DB: Therapeutic applications of the insulin-like growth factors. Growth Horm. IGF Res. (2004) 14:301–308.
   PubMed Web of Science ®Google Scholar
• MUSARO A, McCULLAGH KJA, PAUL A et al: Localized IGF-1 transgene sustains hypertrophy and regeneration in senescent muscle. Nat. Genetics (2001) 27:195–200.
   PubMed Web of Science ®Google Scholar
• FROSTICK S, YIN Q, KEMP G: Schwann cells, neurotrophic factors, and peripheral nerve regeneration. Microsurgery (1998) 18:397–405.
   PubMed Web of Science ®Google Scholar
• STUERENBURG HJ, KUNZE K: Tissue concentrations of nerve growth factor in aging rat heart and skeletal muscle. Muscle Nerve (1998) 21:404–406.
   PubMed Web of Science ®Google Scholar
• KELLER-PECK CR, FENG G, SANES JR, YAN Q, LICHTMAN JW, SNIDER WD: Gilal cell line-derived neurotrophic factor administration in postnatal life results in motor unit enlargement and continuous synaptic remodeling at the neuromuscular junction. Neurosci. (2001) 21:6136–6146.
   PubMed Web of Science ®Google Scholar
• FUNAKOSHI H, BELLUARDO N, ARENAS E et al.: Muscle-derived neurotropin-4 as an activity-dependent trophic signal for adult motor neurons. Science (1995) 268:1495–1499.
   PubMed Web of Science ®Google Scholar
• GOMEZ-PINILLA F, YING Z, OPAZO P, ROY RR, EDGERTON VR: Differential regulation by exercise of BDNF and NT-3 in rat spinal cord and skeletal muscle. Lim NeuroscL (2001) 13:1078–1084.
   Web of Science ®Google Scholar
• GUILLET C, AUGUSTE P, MAYO W, KREHER P, GASCAN H: Ciliary neurotrophic factor is a regulator of muscular strength in aging. Neurosci. (1999) 19:1257–1262.
   PubMed Web of Science ®Google Scholar
• BARTLETT SE, BANKS GB, REYNOLDS AJ, WATERS MJ, HENDRY IA, NOAKES PG: Alterations in ciliary neurotrophic factor signaling inrapsyn deficient mice. J. Neurosci. Res.(2001) 64:575–581.
   PubMed Web of Science ®Google Scholar
• ROTH SM, SCHRAGER MA, FERRELL RE et al.: CNTF genotype is associated with muscular strength and quality in humans across the adult age span.Appl Physiol (2001) 90:1205–1210.
   PubMed Web of Science ®Google Scholar
• PEROULAKIS ME, FORGER NG: Ciliary neurotrophic factor increases muscle fiber number in the developing levator ani muscle of female rats. Neurosci. Lett. (2000) 296:73–76.
   PubMed Web of Science ®Google Scholar
• ENGLISH AW: Cytokines, growth factors and sprouting at the neuromuscular junction. J. Neurocytol. (2003) 32:943–960.
   PubMedGoogle Scholar
• MOUSAVI K, MIRANDA W, PARRY DJ: Neurotrophic factors enhance the survival of muscle fibers in EDL, but not SOL, after neonatal nerve injury. Am. J. Physiol (2002) 283:C950–959.
   Web of Science ®Google Scholar
• FRAYSSE B, GUILLET C, HUCHET-CADIOU C, CAMERINO DC, GASCAN H, LEOTY C: Ciliary neurotrophic factor prevents unweighting-induced functional changes in rat soleus muscle. J. Appl. Physiol (2000) 88: 1623–1630.
   Google Scholar
• MITSUMOTO H, IKEDA K, HOLMLUND T et al.: The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann. Neurol (1994) 36:142–148.
   PubMed Web of Science ®Google Scholar
• ELLIOTT JLM, SNIDER WDM: Motor neuron growth factors. Neurology(1996) 47\(Suppl. 2):475–535.
   Google Scholar
• ZHANG J, LINEAWEAVER WC, OSWALD T, CHEN Z, ZHANG F: Ciliary neurotrophic factor for acceleration of peripheral nerve regeneration: an experimental study. J. Reconstr. Microsurg. (2004) 20:323–337.
   PubMed Web of Science ®Google Scholar
• GURA T: Obesity drug pipeline not so fat. Science (2003) 299:849–852.
   PubMed Web of Science ®Google Scholar
• GRUNDMAN M, CAPPARELLI E, KIM HT: A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Se/. (2003) 73:539–553.
   PubMed Web of Science ®Google Scholar
• KUREK J: AM424: history of a novel drug candidate. Clio. Exp. Pharmacol Physiol (2000) 27:553–557.
   PubMed Web of Science ®Google Scholar
• KUREK JB, BOWER JJ,ROMANELLA M, KOENTGEN F, MURPHY M, AUSTIN L: The role of leukemia inhibitory factor in skeletal muscleregeneration. Muscle Nerve (1997) 20:815–822.
   PubMed Web of Science ®Google Scholar
• AUSTIN L, BOWER JJ, BENNETT TM et al.: Leukemia inhibitory factor ameliorates muscle fiber degeneration in the mdx mouse. Muscle Nerve (2000) 23:1700–1705.
   PubMed Web of Science ®Google Scholar
• GREGOREVIC P, WILLIAMS DA, LYNCH GS: Effects of leukemia inhibitory factor on rat skeletal muscles are modulated by clenbuterol. Muscle Nerve (2002) 25:194–201.
   PubMed Web of Science ®Google Scholar
• WHITE JD, DAVIES M,GROUNDS MD: Leukaemia inhibitory factor increases myoblast replication and survival and affects extracellular matrix production: combined in vivo and in vitro studies in post-natal skeletal muscle. Cell Tissue Res. (2001) 306:129–141.
   PubMed Web of Science ®Google Scholar
• RIMER M, PRIETO AL, WEBER JL et al: Neuregulin-2 is synthesized by motor neurons and terminal Schwann cells and activates acetylcholine receptor transcription in muscle cells expressing ErbB4. Ma Cell Neurosci. (2004) 26:271–281.
   PubMed Web of Science ®Google Scholar
• CANNELLA B, HOBAN CJ, GAO YL et al.: The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc. Nati Acad. ScL USA (1998) 95:10100–10105.
   PubMed Web of Science ®Google Scholar
• COURTNEY J, STEINBACH JH: Age changes in neuromuscular junction morphology and acetylcholine receptor distribution on rat skeletal muscle fibres.Physiol (1981) 320:435–447.
   Web of Science ®Google Scholar
• BANKER BQ, KELLY SS, ROBBINS N: Neuromuscular transmission and correlative morphology in young and old mice. Physiol (1983) 339:355–377.
   Web of Science ®Google Scholar
• SUSSMAN HE: Success for oral antisense therapy. Drug Discov. Today (2003) 8:516–517.
   PubMed Web of Science ®Google Scholar
• BRENNER T, HAMRA-AMITAY Y, EVRON T, BONEVA N, SEIDMAN S, SOREQ H: The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. (2003) 17:214–222.
   PubMed Web of Science ®Google Scholar
• METCALF D, GREENHALGH CJ, VINEY E et al: Gigantism in mice lacking suppressor of cytokine signalling-2. Nature (2000) 405: 1069–1073.
   Google Scholar
• KILE BT, ALEXANDER WS: The suppressors of cytokine signalling (SOCS). Cell Ma Life Sci. (2001) 58:1627–1635.
   PubMed Web of Science ®Google Scholar
• KILE BT, SCHULMAN BA, ALEXANDER WS, NICOLA NA, MARTIN HM, HILTON DJ: The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. (2002) 27:235–241.
   PubMed Web of Science ®Google Scholar
• ALEXANDER WS, HILTON DJ: The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Ann. Rev Immunol (2004) 22:503–529.
   PubMed Web of Science ®Google Scholar
• GREENHALGH CJ, METCALF D, THAUS AL et al.: Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. (2002) 277:4018–40184.
   PubMed Web of Science ®Google Scholar
• MERRIAM GR, SCHWARTZ RS, VITIELLO MV: Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine (2003) 22:41–48.
   PubMed Web of Science ®Google Scholar
• GHIGO E, ARVAT E, GIORDANO R et al.: Biologic activities of growth hormone secretagogues in humans. Endocrine (2001) 14:87–93.
   PubMed Web of Science ®Google Scholar
• EHLERS MR: Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program. Endocrine (2001) 14:137–141.
   PubMed Web of Science ®Google Scholar
• ZACHWIEJA JJ, YARASHESKI KE: Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older?Phys. Ther. (1999) 79:76–82.
   Google Scholar
• FUH VL, BACH MA: Growth hormone secretagogues: mechanism of action and use in aging. Growth Horm. IGF Res. (1998)8:13–20.
   PubMed Web of Science ®Google Scholar
• JANSEN M, DARBY I, ABRIBAT T, DUBREUIL P, FERDINANDI ES, HARDY JG: Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int. J. Pharm. (2004) 276:75–81.
   PubMed Web of Science ®Google Scholar
• MATRIANO JA, CORMIER M, JOHNSON J et al.: Macroflwc microprojection array patch technology: a new and efficient approach for intracutaneous immunization. Pharm. Res. (2002) 19:63–70.
   PubMed Web of Science ®Google Scholar
• McPHERRON AC, LAWLER AM, LEE SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature (1997) 387:83–90.
   PubMed Web of Science ®Google Scholar
• McPHERRON AC, LEE SJ: Double muscling in cattle due to mutations in the myostatin gene. Proc. Nat] Acad. Sci. USA (1997) 94:12457–12461.
   PubMed Web of Science ®Google Scholar
• THOMAS M, LANGLEY B, BERRY C: Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. J. Biol. Chem. (2000) 275:40235–40243.
   PubMed Web of Science ®Google Scholar
• RIOS R, CARNEIRO I, ARCE VM, DEVESA J: Myostatin is an inhibitor of myogenic differentiation. Am. I Physic] (2002) 282:C993–C999.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-CADAVID NE TAYLOR WE, YARASHESKI K et al: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Nat] Acad. Sci. USA (1998) 95:14938–14943.
   PubMed Web of Science ®Google Scholar
• MARCELL TJ, HARMAN SM,URBAN RJ, METZ DD, RODGERS BD, BLACKMAN MR: Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. Am. J. Physiol (2001) 281:E1159–E1164.
   Web of Science ®Google Scholar
• WHITTEMORE LA, SONG K, LI X et al.: Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Comm. (2003) 300:965–971.
   PubMed Web of Science ®Google Scholar
• LIN J, ARNOLD HB, DELLA-FERA MA, AZAIN MJ, HARTZELL DL, BAILE CA: Myostatin knockout in mice increases myogenesis and decreases adipogenesis. Biochem. Biophys. Res. Comm. (2002) 291:701–706.
   PubMed Web of Science ®Google Scholar
• WAGNER KR, McPHERRON AC, WINIK N, LEE SJ: Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann. Nemo]. (2002) 52:832–836.
   PubMed Web of Science ®Google Scholar
• ZIMMERS TA, DAVIES MV,KONIARIS LG et al: Induction of cachexia in mice by systemically administered myostatin. Science (2002) 296:1486–1488.
   PubMed Web of Science ®Google Scholar
• WHITTEM ORE LA, SONG K, LI X et al.: Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. (2003) 300:965–971.
   PubMed Web of Science ®Google Scholar
• BOGDANOVICH S, KRAG TO, BARTON ER et al.: Functional improvement of dystrophic muscle by myostatin blockade. Nature (2002) 420:418–421.
   PubMed Web of Science ®Google Scholar
• LIU W, THOMAS SG, ASA SL, GONZALEZ-CADAVID N, BHASIN S, EZZAT S: Myostatin is a skeletal muscle target of growth hormone anabolic action. Clin. Endocrinol Metal,. (2003) 88:5490–5496.
   PubMed Web of Science ®Google Scholar
• ROTH SM, WALSH S: Myostatin: a therapeutic target for skeletal muscle wasting. Carr. Opin. Clin. Num. Metal,. Care (2004) 7:259–263.
   PubMed Web of Science ®Google Scholar
• RYALL JG, GREGOREVIC P,PLANT DR, SILLENCE MN,LYNCH GS: 32-Agonist fenoterol has greater effects on contractile function of rat skeletal muscles than clenbuterol. Am. J. Physic] Regal. Integr. Comp. Physic] (2002) 283:R1386–R1394.
   PubMed Web of Science ®Google Scholar
• RYALL JG, PLANT DR,GREGOREVIC P, SILLENCE MN, LYNCH GS: Fenoterol treatment ameliorates sarcopenia and improves muscle function in aged rats. J. Physic] (2004) 555:175–188.
   Google Scholar
• RYALL JG, PLANT DR, LYNCH GS: Making old muscles young again: a therapeutic role for 132-agonists? Physic] News (2004) 56:33–35.
   Web of Science ®Google Scholar
• VUKOVICH MD, STUBBS NB, BOHIKEN RM: Body composition in 70-year-old adults responds to dietary P-hydroxy-P-methylbutyrate similarly to that of young adults. J. Num. (2001) 131:2049–2052.
   Google Scholar
• TERJUNG RL, CLARKSON P,EICHNER ER et al:The physiological and health effects of oral creatine supplementation. Med. Sci. Sports Exerc. (2000) 32:706–717.
   PubMed Web of Science ®Google Scholar
• PERSKY AM, BRAZEAU GA: Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev (2001) 53:161–176.
   PubMed Web of Science ®Google Scholar
• GOTSHALK LA, VOLEK JS, STARON RS, DENEGAR CR, HAGERMAN FC, KRAEMER WJ: Creatine supplementation improves muscular performance in older men. Med. Sci. Sports Exerc. (2002) 34:537–543.
   PubMed Web of Science ®Google Scholar
• TARNOPOLSKY MA: Potential benefits of creatine monohydrate supplementation in the elderly. Carr. Opin. Clin. Num. Metal,. Care (2000) 3:497–502.
   PubMedGoogle Scholar
• TARNOPOLSKY MA, MAHONEY DJ, VAJSAR J et al.: Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology (2004) 62:1771–1777.
   PubMed Web of Science ®Google Scholar
• GROENEVELD GJ, VELDINK JH, VAN DER TWEEL I et al.: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol (2003) 53:437–445.
   PubMed Web of Science ®Google Scholar
• BAKER SK, TARNOPOLSKY MA: Targeting cellular energy production in neurological disorders. Expert Opin. Investig. Drugs (2003) 12:1655–1679.
   PubMed Web of Science ®Google Scholar
• MORELY JE: Drugs, aging, and the future. Gerontol. (2002) 57A:M2–M6.
   Google Scholar
• MORELY JE: The top 10 hot topics in aging. J. Cerontol (2004) 59A:24–33.
   Google Scholar